Tarsus to Buy Alkeus Pharmaceuticals for 800 Million
Tarsus Pharmaceuticals announced a cash and stock deal to acquire Alkeus Pharmaceuticals for up to 800 million dollars to expand its eye disease pipeline. The acquisition adds an experimental oral therapy for Stargardt disease, which the company estimates could represent a billion dollar opportunity.
Xurve View
Insights:
Xurve View
TARSUS PHARMACEUTICALS INC will acquire Alkeus Pharmaceuticals for up to $800 million to secure a late-stage therapy for a rare blinding disease. The deal includes an upfront payment of $450 million, consisting of $270 million in cash and $180 million in common stock. The acquisition provides Tarsus with a potential first-to-market oral treatment for Stargardt disease, which currently has no approved therapies in the United States.
